HEPA - Hepion Pharmaceuticals Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: Other OTC Current Price & Safety Score Price: 0.13 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): -100.00 StockBond Score: -5.56 Company Description Hepion Pharmaceuticals Inc a USbased biopharmaceutical entity is dedicated to developing therapeutic interventions for chronic hepatic ailments Central to their efforts is Rencofilstat a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease It is currently progressing through clinical development for nonalcoholic steatohepatitis NASH and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH Moreover Rencofilstat has exhibited antiviral properties against hepatitis B C and D viruses through diverse mechanisms The company established in 2013 and situated in Edison New Jersey rebranded as Hepion Pharmaceuticals Inc in July 2019 having previously operated as ContraVir Pharmaceuticals Inc